share_log

Tiziana Life Sciences Doses First Patient With Intranasal Foralumab With Moderate Alzheimer's Disease

Benzinga ·  Dec 17 20:06
Tiziana Life Sciences Doses First Patient With Intranasal Foralumab With Moderate Alzheimer's Disease
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment